Case Report
IgG4-Related Hepatic Pseudotumor Masquerading as a Klatskin Tumor
Table 1
The literature review of reported IgG4-related hepatic IPTs to date.
| | Author | Year | Age | Sex | Tumor number/location | Biopsy | Biopsy method | Resection | Initial diagnostic impression | Serum IgG4 |
| | Adachi K [14] | 2017 | 60 | M | 1/Segment 3 | N | | Y | Hepatic cancer | Elevated | | Adachi Y [15] | 2020 | 80s | F | 1 | Y | Unspecified | N | Hepatic IPT | Elevated | | Ahn KS [9] | 2012 | 58 | M | 1 | | | Y | Recurrence of Klatskin tumor | | | | | 60 | M | 1 | | | Y | Malignancy | | | | | 76 | M | 2 | | | N | Hepatic IPT | | | | | 52 | M | 1 | | | N | Hepatic IPT | | | Buchter M [16] | 2018 | 58 | M | | Y | Unspecified | N | Hodgkin’s lymphoma | 2528 | | Chia JS [17] | 2020 | 53 | M | | N | | Y | | | | Chung JW [18] | 2019 | 67 | M | 1 | Y | Percutaneous | Y | Abscess, cancer | 2215 | | Fujisaki H [19] | 2016 | 75 | F | 1/Segment 7 | N | | Y | Hepatic IPT | Serum normal, bx elevated | | Hamano A [6] | 2020 | 71 | M | 1/Segment 3 | Y | Percutaneous | N | Hepatic cholangiocarcinoma | 180 | | Hastir D [20] | 2013 | 50 | F | 1/Segment 5 | N | | Y | Hepatocellular carcinoma | | | Horiguchi S [21] | 2012 | 76 | M | 1/Segment 2 | Y | Laparoscopic | N | | 819 | | Itazaki Y [2] | 2021 | 75 | F | 1 | | | Y | Cholangiocarcinoma | | | Kanno a [22] | 2005 | 48 | M | | N | | Y | Liver metastasis from cholangiocarcinoma | 2150 | | Kataoka K [23] | 2017 | 79 | M | | Y | Unspecified | N | | Elevated | | Kim F [24] | 2011 | 58 | M | 1/Segment 4 | Y | Percutaneous | N | | 1470 | | Lee YS [25] | 2013 | 59 | M | 1/Segment 5 | Y | Percutaneous | N | Inoperable gallbladder cancer | 75 | | Legkiy O [26] | 2019 | 60 | M | 2/Segment 2 & 6 | Y | Percutaneous | Y | | 19.1 | | Matsuo Y [27] | 2014 | 74 | M | 1/Segment 8 | N | | Y | Liver metastasis from GIST | | | Miyajima S [28] | 2017 | 50 | F | 1 | Y | Unspecified | N | Cholangiocarcinoma | 241 | | Mulki R [29] | 2015 | 50 | M | 2 | N | | Y | Abscess with impending rupture | >182 | | Naitoh I [30] | 2009 | 77 | M | 1/Segment 3 | N | | Y | Intrahepatic cholangitis | 231 | | Patel H [10] | 2018 | 48 | M | 1 | Y | Unspecified | N | | 2228 | | Shibata M [4] | 2016 | 72 | M | 1/Segment 7 | Y | Percutaneous | N | | 137 | | Uchida K [31] | 2007 | 54 | M | 1/Segment 4 | Y | Unspecified | N | Pancreatic cancer with liver metastasis | 213 | | Vadi S [32] | 2018 | 54 | M | 1/Gallbladder fossa | Y | Unspecified | N | | 356 | | Wang M [33] | 2020 | 78 | M | 1/Segment 4 | N | | Y | Cholangiocarcinoma | | | Yang L [34] | 2015 | 60 | M | 1/Segment 3 | Y | Unspecified | N | | 1590 | | Yueh HZ [35] | 2021 | 47 | M | Multiple | Y | Percutaneous | N | Metastatic cancer | 1786 | | Zen Y(16 cases) [36] | 1990–2005 | Avg 67 (56–82) | 11M 5F | | N | | Y | (All resected) | Hilar cholangiocarcinoma (8), intrahepatic cholangiocarcinoma (5), malignant hepatic tumor, undetermined origin (2), metastatic carcinoma (1) |
|
|
